The Perera laboratory focuses on pharmacogenomics (using a patient's genome to predict drug response) in minority populations. Our goal is to make precision medicine available to all.
Dr. Minoli Perera PharmD, PhD
Dr. Perera is an Associate Professor within the Department of Pharmacology and Center for Pharmacogenomics at the Feinberg School of Medicine with expertise in pharmacokinetics, clinical pharmacology and human genetics.
What We Do
African American Genomic Medicine
Prescribing the right drug at the right dose for the right patient
Anticoagulants remain some of the most dangerous drugs taken in the US. We investigate if a patient's genome can predict the therapeutic dose, or adverse effects (e.g. bleeding) associated with these drugs. This information could be used to help doctors select the safest and most effective medication for each patient.
Genomics of Drug Metabolism
Genetic biomarkers that regulate drug metabolism
The liver metabolizes over 70% of drugs currently prescribed in the US. However, we still do not understand the genes and genetic mutations that regulate these important hepatic enzymes. We are investigating the role of genetic variation in the regulation of gene expression of drug metabolizing enzymes (DMEs) in African Americans (funded NIMDH). Click here for details on this project.
Pharmacogenomics of Inflammatory Bowel Disease
Genetic biomarkers to predict primary non-response.
Biologic therapies have been a revolution in the treatment of inflammatory bowel disease. However there remains a subset of patients that do not respond to these drugs and hence receive no clinical benefit. Moreover, this subset will be exposed to potential side-effects from biologic therapy. Genetic biomarkers that can predict if a patient will respond to biologic therapy would enable physicians to make better decision for patients and limit unwanted drug exposure to those with little chance of benefit.
Using the electronic health record to personalize healthcare.
The Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The Network brings together researchers with a wide range of expertise in genomics, statistics, ethics, informatics, and clinical medicine from leading medical research institutions across the country to conduct research in genomics, including discovery, clinical implementation and public resources. we are involved in the analysis on the newest eMERGE sequencing data. We hope to identify novel variants in genes important to drug response.
African American Cardiovascular Pharmacogenomics Consortium
ACCOuNT is a NIMHD funded Collaborative Consortium aimed at accerateing the pace of pharmacogenomic discovery and translation in African Americans. We have brought together investigators at 2 major US cities (Chicago and DC), as well as clinical, pharmacogenomic and informatics experts to build a sustainable research consortium. Click here for more details. We have also been featured in PGRN HUB.
Meet the Lab
Senior Research Associate
Dr. Friedman has worked extensively in cancer genomics and pharmacogenomics prior to joining the lab. She is currently managing the projects associated with the ACCOuNT Consortium.
Past Lab members
Off to bigger and better things!
Keston Aquino-Michaels - Data Scientist at SparkBeyond.
Erin Smithberger - Graduate student at University of North Carolina
Ijezie Ikwuezunma - Senior at Washington and Lee Univeristy and winner of the Johnson Opportunity Grant
Stephanie Poindexter - Graduate Student in Anthropology, Oxford Brooks University
Megan Flynn - Georgetown Medical student
Lucia Cortejoso - PharmD in Hospital General Univeritario, Spain
Mary Young - Medical Resident
High School students
Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clin Pharmacol Ther. 2017 Feb 15 (epub ahead of print).
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, Patel S, O’Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Konkashbaev A, Cavallari LH, Perera MA. J Thromb. Haemost. 2017 Jan 30 (epub ahead of print)
Population Differences in the Pharmacokinetics of S-warfarin Among African Americans, Asians and Caucasians: Implications for Pharmacogenetic Dosing Algorithms. Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM, Scordo MG, Nutescu E, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Yakahashi H. Pharmacogenomics J. 2016 June; 4(5):513-520
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, Takahashi H. Pharmacogenomics. 2015 Mar; 2016(3):217-25.
Population specific genomics identifies predictor of Venous Thromboembolism in African Americans. Hernandez W, Gamazon ER, Smithberger E, O’Brien T, Harrelson A, Tuck M, Barbour A, Kittles RA, Cavallari LH, Perera MA. Blood 2016 Apr. 14; 127(15): 1923-1929. Press Release by American Society of Hematology, Commentary in Blood 127 (15).
Population-specific single nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson J, Klein TE, Bustamante CD, Roden D, Shaffer C, Denny JC, Zehnder JL, Altman RB. Molecular Genetics &Genomic Medicine 2016 Jun 21;4(5):513-520
We could all use a little help from our friends.
University of Illinois, Chicago
Director, Pharmacogenomics Laboratory, Pharmacy Practice
Pharmacogenomics Research Network
The PGRN catalyzed pharmacogenomics discoveries both nationally and internationally through the conduct of collaborative research focused on the discovery and translation of the genetic determinants of drug response, in order to enable safer and more effective drug therapies.
A collaboration to further Precision medicine
Leaders at the National Institutes of Health(NIH) Pharmagenomics Research Network (PGRN) and the RIKEN Center for Genomic Medicine(CGM) in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. Using genomewide approaches, identify genetic variants that contribute to individual responses to medicines, including rare and serious side effects.
Official Lab Photo
Lab Photo Fall 2016
Northwestern University Downtown Quad